Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Capsules × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4 Tumor-Agnostic 3 Plasma cell 2 Other hematologic neoplasm 2 Myeloid 2 Lymphoid 2 CNS 2 Sarcoma 1 Other solid neoplasm 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Gastrointestinal 1 Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 688 Paclitaxel 676 Cyclophosphamide 633 Docetaxel 552 Capecitabine 467 Letrozole 402 Carboplatin 391 Fulvestrant 372 Doxorubicin 330 Tamoxifen 285 pembrolizumab 270 Epirubicin 249 Anastrozole 249 exemestane 235 pertuzumab 221 Bevacizumab 214 Radiotherapy 211 Gemcitabine 210 Vinorelbine 188 palbociclib 182 Lapatinib 175 130-nm albumin-bound paclitaxel 168 Albumin-Bound Paclitaxel 156 Exercise 146 eribulin 144 Magnetic Resonance Spectroscopy 143 Taxes 134 Fluorouracil 131 Everolimus 118 Cisplatin 117

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03262935 2023-10-19

TULIP

Byondis B.V.

Phase 3 Completed

437 enrolled 17 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡